| scholarly article | Q13442814 |
| P50 | author | Gustav Gaudernack | Q5621121 |
| Martin Pule | Q39819805 | ||
| Sébastien Wälchli | Q41631179 | ||
| Else Marit Inderberg | Q42333928 | ||
| Gunnar Kvalheim | Q91362816 | ||
| P2093 | author name string | Steinar Aamdal | |
| Jon Amund Kyte | |||
| Anne Faane | |||
| Kari Lislerud | |||
| Paal Brunsvig | |||
| P2860 | cites work | Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 | Q24633445 |
| Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study | Q24652592 | ||
| Specific Association of Human Telomerase Activity with Immortal Cells and Cancer | Q27860801 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells | Q29616205 | ||
| Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia | Q29617590 | ||
| Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major | Q29619125 | ||
| Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | Q29620130 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4 + T- Cells, Which Dampen CD8 + T-cell Antitumor Reactivity | Q30040092 | ||
| A practical approach to T-cell receptor cloning and expression | Q34088001 | ||
| Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory | Q34190038 | ||
| Tumor antigen-specific T helper cells in cancer immunity and immunotherapy | Q34433202 | ||
| Neoantigens in cancer immunotherapy. | Q34470074 | ||
| CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit | Q34601772 | ||
| Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells | Q34823085 | ||
| hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes | Q34995761 | ||
| Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation | Q35784529 | ||
| Rapid generation of NY-ESO-1-specific CD4(+) THELPER1 cells for adoptive T-cell therapy | Q35799353 | ||
| Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells | Q35947812 | ||
| TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. | Q36057454 | ||
| Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. | Q36194834 | ||
| Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma | Q36206582 | ||
| Polyfunctional T cell responses are a hallmark of HIV-2 infection | Q36618086 | ||
| Engineered T cells for anti-cancer therapy. | Q36755385 | ||
| T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy | Q36799229 | ||
| Telomerase and cancer therapeutics | Q37078833 | ||
| Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. | Q37095348 | ||
| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade | Q37173548 | ||
| Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion | Q37201309 | ||
| Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. | Q37599478 | ||
| Functional avidity: a measure to predict the efficacy of effector T cells? | Q38066211 | ||
| Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance | Q38124438 | ||
| Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model | Q38445486 | ||
| Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors | Q38525034 | ||
| GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade | Q38782845 | ||
| CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes | Q40669542 | ||
| HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity | Q40684761 | ||
| Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen | Q41870799 | ||
| High frequency of T cells specific for cryptic epitopes in melanoma patients | Q42141424 | ||
| Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients | Q43786937 | ||
| T-helper-1-cell cytokines drive cancer into senescence | Q44539245 | ||
| Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells | Q45865490 | ||
| A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy | Q45866398 | ||
| Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. | Q46128909 | ||
| Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination | Q46885041 | ||
| Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. | Q50992560 | ||
| Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. | Q51817556 | ||
| Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. | Q51983318 | ||
| Transgenic mice with a diverse human T cell antigen receptor repertoire. | Q52902257 | ||
| Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. | Q54238337 | ||
| Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. | Q54580812 | ||
| Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer | Q56815464 | ||
| Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer | Q57152489 | ||
| HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes | Q78837049 | ||
| Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination | Q81628720 | ||
| P433 | issue | 12 | |
| P304 | page(s) | e1249090 | |
| P577 | publication date | 2016-10-24 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy | |
| P478 | volume | 5 |
| Q93039761 | Targeting Cancer with Genetically Engineered TCR T Cells |
| Q102206484 | Targeting telomerase with an HLA class II-restricted TCR for cancer immunotherapy |
| Q64252676 | Telomerase-Targeted Cancer Immunotherapy |
| Q92586165 | Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination |
Search more.